A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 105
Summary
- Conditions
- Fallopian Tube Cancer
- Bladder Urothelial Carcinoma
- Breast Cancer
- Marginal Zone Lymphoma
- Small Lymphocytic Leukemia
- Cholangiocarcinoma
- Other Solid Tumors
- Renal Cell Carcinoma
- Colorectal Cancer
- Diffuse Large B Cell Lymphoma (DLBCL)
- Non Hodgkin Lymphoma
- Ovarian Cancer
- Non -Small Cell Lung Cancer
- Lymphoplasmacytic Lymphoma
- Indolent B-cell Lymphomas
- Esophageal Cancer
- Mucosa Associated Lymphoid Tissue
- Waldenstrom's Disease
- Follicular Lymphoma
- Gastric Cancer
- Primary Peritoneal Cancer
- Pancreatic Adenocarcinoma
- Mantle Cell Lymphoma
- Head and Neck Cancer
- Melanoma
- Hepatic Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability and efficacy of CDX-1140 alone (Part 1) or in combination with CDX-301 (Part 2), pembrolizumab (Part 3), or chemotherapy (Part 4) in patients with cancer. Eligible patients that enroll to the dose-escalation...
This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability and efficacy of CDX-1140 alone (Part 1) or in combination with CDX-301 (Part 2), pembrolizumab (Part 3), or chemotherapy (Part 4) in patients with cancer. Eligible patients that enroll to the dose-escalation portion of the study will be assigned to one of several dose levels of CDX-1140. The dose-escalation part of the study will test the safety profile of CDX-1140, alone or in combination with CDX-301, pembrolizumab or chemotherapy and determine which dose(s) of CDX-1140 will be studied in the expansion portions of the study. All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.
Tracking Information
- NCT #
- NCT03329950
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Not Provided
Get Well Soon